Ph.D. William Benton Jones - 20 Dec 2024 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
SVP, Pharmaceutical Development
Signature
/s/ Leiv Lea, as Attorney-in-Fact for William Benton Jones, Ph.D.
Issuer symbol
CRVS
Transactions as of
20 Dec 2024
Net transactions value
$0
Form type
4
Filing time
23 Dec 2024, 16:39:46 UTC
Previous filing
07 May 2024
Next filing
06 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 20 Dec 2024 Common Stock 300,000 $4.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

SVP, Pharmaceutical Development